# Matridx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/matridx

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.matridx.com
- Total disclosed funding: $31M
- Latest round: Series B (Jan 20, 2021)
- Investors on record: 4

## About

Established in 2019 and based in Hangzhou, China, Matridx is an innovative technology enterprise that focuses on the molecular diagnosis of infectious diseases. The company has acquired more than 100 patents. It has cooperated with Peking Union Medical College Hospital, Huashan Hospital of the Shanghai FuDan University, and Guangzhou Institute of Respiratory Health. In 2023, Matridx launched Targeted NGS (tNGS) for Pathogenic Microorganisms. In December 2023, Matridx closed a series C+ funding from new investor Zhejiang Yuhang Industrial Transformation & Upgrading Investment and Jiujiang Kuntai Equity Investment Fund Management. In July 2024, the firm closed a strategic investment.

The company provides the diagnosis of infectious diseases solutions for patients, developed gene editing (CRISPR/Cas) and high-throughput sequencing (NGS) as the technology platforms, and adopted the technology of genetic testing, big data analysis, and artificial intelligence. Specific products and services include Pathogen Macro Gene Banker, mNGS Assay Kit, microbial mMGS solution, and SARS-CoV -2 nucleic acid detecting solution. It also developed an automated Library prep instrument.

The company’s revenue is generated by providing molecular diagnostic solutions for infectious diseases.

The company will use the funding to develop product pipelines, as well as register and commercialize the medical device product.

## Funding rounds

- Series B, Jan 20, 2021, $31M — Puhua Capital, CD Capital, Proxima Ventures, Qianhai Ark Capital
- Series A, Aug 1, 2020 — CD Capital

## Investors

- CD Capital — Series A, Series B
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series B
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series B